Nanoparticle-induced vascular blockade in human prostate cancer
- PMID: 20587786
- PMCID: PMC2974592
- DOI: 10.1182/blood-2010-03-274258
Nanoparticle-induced vascular blockade in human prostate cancer
Abstract
The tumor-homing pentapeptide CREKA (Cys-Arg-Glu-Lys-Ala) specifically homes to tumors by binding to fibrin and fibrin-associated clotted plasma proteins in tumor vessels. Previous results show that CREKA-coated superparamagnetic iron oxide particles can cause additional clotting in tumor vessels, which creates more binding sites for the peptide. We have used this self-amplifying homing system to develop theranostic nanoparticles that simultaneously serve as an imaging agent and inhibit tumor growth by obstructing tumor circulation through blood clotting. The CREKA nanoparticles were combined with nanoparticles coated with another tumor-homing peptide, CRKDKC, and nanoparticles with an elongated shape (nanoworms) were used for improved binding efficacy. The efficacy of the CREKA peptide was then increased by replacing some residues with nonproteinogenic counterparts, which increased the stability of the peptide in the circulation. Treatment of mice bearing orthotopic human prostate cancer tumors with the targeted nanoworms caused extensive clotting in tumor vessels, whereas no clotting was observed in the vessels of normal tissues. Optical and magnetic resonance imaging confirmed tumor-specific targeting of the nanoworms, and ultrasound imaging showed reduced blood flow in tumor vessels. Treatment of mice with prostate cancer with multiple doses of the nanoworms induced tumor necrosis and a highly significant reduction in tumor growth.
Figures
Similar articles
-
The antitumor activity of tumor-homing peptide-modified thermosensitive liposomes containing doxorubicin on MCF-7/ADR: in vitro and in vivo.Int J Nanomedicine. 2015 Mar 19;10:2229-48. doi: 10.2147/IJN.S79840. eCollection 2015. Int J Nanomedicine. 2015. PMID: 25834435 Free PMC article.
-
Cys-Arg-Glu-Lys-Ala-superparamagnetic iron oxide-Cy7 nanoparticles.2008 Aug 8 [updated 2008 Oct 15]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2008 Aug 8 [updated 2008 Oct 15]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 20641920 Free Books & Documents. Review.
-
Targeted Drug Delivery and Image-Guided Therapy of Heterogeneous Ovarian Cancer Using HER2-Targeted Theranostic Nanoparticles.Theranostics. 2019 Jan 24;9(3):778-795. doi: 10.7150/thno.29964. eCollection 2019. Theranostics. 2019. PMID: 30809308 Free PMC article.
-
Peptide targeted tripod macrocyclic Gd(III) chelates for cancer molecular MRI.Biomaterials. 2013 Oct;34(31):7683-93. doi: 10.1016/j.biomaterials.2013.06.057. Epub 2013 Jul 14. Biomaterials. 2013. PMID: 23863450 Free PMC article.
-
Magnetic nanoformulations for prostate cancer.Drug Discov Today. 2017 Aug;22(8):1233-1241. doi: 10.1016/j.drudis.2017.04.018. Epub 2017 May 16. Drug Discov Today. 2017. PMID: 28526660 Free PMC article. Review.
Cited by
-
Actively Targeted Nanomedicines: A New Perspective for the Treatment of Pregnancy-Related Diseases.Reprod Sci. 2024 Mar 29. doi: 10.1007/s43032-024-01520-z. Online ahead of print. Reprod Sci. 2024. PMID: 38553575 Review.
-
Morphologically transformable peptide nanocarriers coloaded with doxorubicin and curcumin inhibit the growth and metastasis of hepatocellular carcinoma.Mater Today Bio. 2023 Dec 12;24:100903. doi: 10.1016/j.mtbio.2023.100903. eCollection 2024 Feb. Mater Today Bio. 2023. PMID: 38130427 Free PMC article.
-
The role of coagulome in the tumor immune microenvironment.Adv Drug Deliv Rev. 2023 Sep;200:115027. doi: 10.1016/j.addr.2023.115027. Epub 2023 Jul 28. Adv Drug Deliv Rev. 2023. PMID: 37517779 Free PMC article. Review.
-
Advances of medical nanorobots for future cancer treatments.J Hematol Oncol. 2023 Jul 14;16(1):74. doi: 10.1186/s13045-023-01463-z. J Hematol Oncol. 2023. PMID: 37452423 Free PMC article. Review.
-
Fabrication of Antibody Conjugated Super Magnetic Oxide Nanoparticles for Early Detection of Prostate Cancer.Asian Pac J Cancer Prev. 2023 Jun 1;24(6):2089-2097. doi: 10.31557/APJCP.2023.24.6.2089. Asian Pac J Cancer Prev. 2023. PMID: 37378940 Free PMC article.
References
-
- Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71–96. - PubMed
-
- Macintosh CA, Stower M, Reid N, Maitland NJ. Precise microdissection of human prostate cancers reveals genotypic heterogeneity. Cancer Res. 1998;58(1):23–28. - PubMed
-
- Ruijter ET, van de Kaa CA, Schalken JA, Debruyne FM, Ruiter DJ. Histological grade heterogeneity in multifocal prostate cancer: biological and clinical implications. J Pathol. 1996;180(3):295–299. - PubMed
-
- Miller GJ, Cygan JM. Morphology of prostate cancer: the effects of multifocality on histological grade, tumor volume and capsule penetration. J Urol. 1994;152(5, pt 2):1709–1713. - PubMed
-
- Jain RK, Munn LL, Fukumura D. Dissecting tumour pathophysiology using intravital microscopy. Nat Rev Cancer. 2002;2(4):266–276. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- CA 30199/CA/NCI NIH HHS/United States
- U54 CA119335/CA/NCI NIH HHS/United States
- P50-CA128346/CA/NCI NIH HHS/United States
- P01 CA104898/CA/NCI NIH HHS/United States
- P30 CA030199/CA/NCI NIH HHS/United States
- HHSN261200800001C/CA/NCI NIH HHS/United States
- P01-CA104898/CA/NCI NIH HHS/United States
- R01 CA124427/CA/NCI NIH HHS/United States
- P01-CA124427/CA/NCI NIH HHS/United States
- P50 CA128346/CA/NCI NIH HHS/United States
- P01-CA119335/CA/NCI NIH HHS/United States
- HHSN261200800001E/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical